All In Biotech

Drug Trial Radar · NCT05409326

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

A Phase I Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jun 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 2022

Primary completion

Jun 2023

Study completion Aug 2023

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.

Conditions

  • Atopic Dermatitis

Interventions

  • TQH2722 injectionDrug

    TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.

  • Placebo to match TQH2722Drug

    TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE)Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  2. Serious adverse events (SAE)Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  3. Blood biochemistryTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  4. Coagulation functionTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  5. Blood routineTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  6. UrinalysisTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  7. Blood pressureTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  8. PulseTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  9. Body temperatureTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  10. SkinTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  11. Mucous membranesTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  12. Lymph nodesTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  13. HeadTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  14. NeckTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  15. ChestTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  16. AbdomenTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  17. SpineTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  18. LimbsTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
  19. 12-lead electrocardiogramTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.